Gentium S.p.A.'s (GENT) first-quarter net income was 0.74 million euros compared to a net loss of 0.91 million euros in the same period in 2012. Net income per share was 0.05 euros compared to a net loss per share of 0.06 euros last year.
The company posted profit in the latest quarter primarily due to an increase in the volume of Defibrotide sold through the named-patient program, a slight increase in API sales and other income and revenues under the cost sharing agreement entered into with Sigma-Tau. Also contributing to the variance there was an increase in research and development expenses and general and administrative expenses offset by a decrease in sales and marketing and income tax expenses.
Total product sales for the quarter were 7.54 million euros compared to 5.65 million euros for the same period in 2012, an increase of 1.89 million euros or 33%. The increase was primarily due to the higher volume of Defibrotide distributed through the named-patient program, which can be partially attributed due to an increased awareness of Defibrotide and, a decrease in service fees associated with the named-patient program managed by one of our European partners.
Total revenues for the quarter were 8.10 million euros up from 5.66 million euros last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.